Delivery Order SPE2DB22D3501-SPE2DB25FXK78
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $26,451.57 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 150 mg/ml vials. This firm fixed price contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its...
- The Defense Logistics Agency awarded a $35,268.76 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of HEMLIBRA 150 mg/ml vials. This non-competitive delivery order, with an ultimate completion date of June 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 master pharmaceutical supply vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Hemlibra 105 mg/0.7 ml vials. This is a firm fixed-price delivery order with a completion date of September 2, 2025, and will be performed at the vendor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competitively awarded. Hemlibra is a specialty pharmaceutical product used in the treatment of hemophilia,...
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp for Hemlibra 105 mg/0.7 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. Hemlibra is a specialized biopharmaceutical used in the treatment of hemophilia, reflecting the critical nature of pharmaceutical procurement for military and federal healthcare systems. The place of performance is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,673.08, is for the supply of 4567331942 HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,564.08 firm fixed-price delivery order is for the supply of HEMLIBRA 150 MG/ML VIALML, a critical medical product, with a period of performance through January 22, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,336.54 firm fixed-price delivery order contract is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award, valued at $16,704.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEMLIBRA 150 MG/ML VIALML. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of August 5, 2024. Amerisourcebergen Drug Corp, through its Corporate Office Division, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,615.66 firm fixed-price delivery order is for the supply of HEMLIBRA 60 MG/0.4 ML VIAL 0.4ML, a specialty medication, with a completion date of November 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK78Delivery Order
The Defense Logistics Agency awarded a $24,673.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEMLIBRA 105 mg/0.7 ml vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product used in hemophilia treatment, reflecting the federal government's need for advanced therapeutic agents to support military and veteran healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The DLA Troop Support Medical contract represents a strategic procurement vehicle supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with access to specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.7k | 9/19/25 |